PARP-3 Inhibitors
1 drugsAbout PARP-3
PARP-3, or poly(ADP-ribose) polymerase 3, is a member of the PARP enzyme family involved in DNA repair, genomic stability, and cell death. While the PARP family has gained attention in drug development, the specific role of PARP-3 is still being elucidated.
Currently, there is no genetic evidence directly linking PARP-3 mutations or variations to specific diseases. The primary therapeutic area associated with PARP-3 targeting is oncology, highlighting the potential of targeting this enzyme to disrupt cancer cell survival mechanisms.
There is one approved drug, RUBRACA, a small molecule targeting PARP-3, developed by PHARMAAND. It was first approved in 2016 and is used in oncology.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Metastatic Endometrial Cancer with only 1 trials.
- phase2 represents biological uncertainty with 58% completion.
Top Drugs
The competitive landscape is concentrated, with PHARMAAND as the only company with an approved drug.
High market concentration suggests potential entry barriers but also opportunity for differentiation.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PARP-3, using small molecule modality.
Exploring alternative modalities like antibodies could provide differentiation.
Clinical Trials 72 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 30 | 22 | 5 | 3 | 81% |
| Phase 2 | 29 | 15 | 8 | 6 | 65% |
| Phase 3 | 10 | 6 | 0 | 4 | 100% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2016 - 2016)
The first and only drug was approved in 2016.
The approval timeline indicates potential for market saturation, requiring novel approaches.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 58 clinical trials targeting PARP-3.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities